Immunotherapy: Clinical Trials

24 trials of Immunotherapy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 recruiting, 4 completed, 3 not yet recruiting, 3 unknown. 24 Phase 3, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 324Recruiting 12, Completed 4, Not yet recruiting 3, Unknown 3, Active not recruiting 1, Terminated 1
Phase 25Recruiting 3, Not yet recruiting 1, Unknown 1

Follow Immunotherapy: new trials by email Literature Review of Immunotherapy trials Research Report on Immunotherapy

Trials (filtered) newest first · largest first

All 24 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Primary Radiotherapy In MEtastatic Lung Cancer
Radiotherapy followed by chemotherapy, Standard of Care (SOC) - Carcinoma, Non-Small-Cell Lung (NSCLC)
Phase 3RecruitingTrans Tasman Radiation Oncology Group4202026-10-302026-10-23
Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS
short-course radiotherapy, Serplulimab, CapOx(Capecitabine+ Oxaliplatin) - Locally Advanced Colon Cancer, pMMR
Phase 3Not yet recruitingFudan University4802026-10-152026-10-16
A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer
standard EBRT+Brachytherapy, Cisplatin, Neoadjuvant chemoimmunotherapy - Locally Advanced Cervical Carcinoma
Phase 3Not yet recruitingFujian Cancer Hospital4862026-09-012026-05-29
Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC
Short-course radiotherapy, Long-course radiotherapy, Immunotherapy - Locally Advanced Rectal Adenocarcinoma, Neoadjuvant Chemoradiation
Phase 2 / Phase 3Not yet recruitingBeijing Friendship Hospital3422026-07-152026-06-17
HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)
Procedure (FOLFOX-HAIC): Max 4 cycles within first 16 weeks., TACE (transarterial chemoembolization) combined with targeted/immunotherapy - Hepatocellular Carcinoma
Phase 3RecruitingBinkui Li3002026-05-152026-05-22
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
LNS8801, Pembrolizumab, Chemotherapy (dacarbazine or temozolomide) - Melanoma (Skin Cancer), Melanoma Stage IIIB-IV
Phase 2 / Phase 3RecruitingLinnaeus Therapeutics, Inc.1352025-08-062026-04-22
Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer
Electroacupuncture combined with immunotherapy, Zilongjin tablet combined with immunotherapy, Immunotherapy - Non-Small Cell Lung Cancer, Electroacupuncture
Phase 2 / Phase 3RecruitingKong Fanming4052025-01-012025-06-24
TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
Immunotherapy, chemotherapy: Paclitaxel/Cisplatin or other guideline recommended regimens, TDLN-sparing RT - Esophageal Carcinoma, Radiotherapy
Phase 3RecruitingFudan University4322024-11-012026-01-07
Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer
Stereotactic Body Radiotherapy, second-line systemic therapy - Metastatic Non-Small Cell Lung Cancer, NSCLC Stage IV
Phase 3RecruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine1042024-09-012024-08-30
Adjuvant vs Surgery Only in Early-stage Recurrent NPC
Immunotherapy,Toripalimab Injection, Chemotherapy,Gemcitabine based regimen - Recurrent Nasopharyngeal Carcinoma
Phase 3RecruitingEye & ENT Hospital of Fudan University1762024-06-252025-07-04
Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma
Chemotherapy, Immunotherapy (Pembrolizumab), radiotherapy - Locally Advanced Esophageal Squamous Cell Carcinoma
Phase 2 / Phase 3RecruitingPeking Union Medical College Hospital1202024-01-122025-04-02
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.
Palliative Radiotherapy, Chemotherapy, Hormone therapy - Metastatic Tumor
Phase 3RecruitingDavid Palma1802023-10-062025-12-31
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
radiotherapy, Platinum-Based Drug, Immunotherapy - Non-small Cell Lung Cancer Stage III
Phase 3UnknownZhejiang Cancer Hospital1052023-09-152023-09-13
Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma
Dendritic cell + Cytokine-induced killer cell (DC+CIK) immunotherapy, Tegafur Only Product - Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
Phase 2 / Phase 3UnknownUniversity of Malaya522023-01-032024-01-10
Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy
SRT, Immunotherapy - Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Phase 3UnknownInstitut Cancerologie de l'Ouest1122022-01-122023-02-21
Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)
the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors. - Acute Lymphoblastic Leukemia, Pediatric, ALL, Infants
Phase 3RecruitingFederal Research Institute of Pediatric Hematology, Oncology and Immunology802021-09-232024-06-28
Documentation of Efficacy of Intralymphatic Allergen Immunotherapy
Grass pollen extract - Alutard Phleum pratense, ALK - Allergic Rhinitis Due to Grass Pollen, Allergic Conjunctivitis of Both Eyes
Phase 3CompletedAarhus University Hospital4502020-02-012025-08-12
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4-10 Oligometastatic Tumors
Palliative Radiation, Chemotherapy, Immunotherapy - Metastatic Tumors
Phase 3Active not recruitingDavid Palma2042019-02-222026-09-30
Traditional Complementary and Alternative Medicine (CAM) Therapy in the Treatment of HIV/AIDS
"Kallunk oxide (Immunotherapy) " - HIV Infections
Phase 3CompletedTraditional Alternative Medicine Research, India10002012-02-272017-03-03
Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Olea Europaea Pollen
Immunotherapy with modified extract of Olea europaea pollen, Placebo - Rhinitis or Rhinoconjunctivitis With or Without Asthma Induced by Hypersensitivity to Olea Europea Pollen
Phase 3CompletedLaboratorios Leti, S.L.1582008-01-012018-02-23

Showing 20 of 24. Sign in to see all of them.

Conditions studied

Carcinoma, Non-Small-Cell Lung (5)  ·  Neoplasm Metastasis (4)  ·  Esophageal Neoplasms (3)  ·  Carcinoma (1)  ·  Carcinoma, Hepatocellular (1)  ·  Colonic Neoplasms (1)  ·  Esophageal Squamous Cell Carcinoma (1)  ·  HIV Infections (1)  ·  Hypersensitivity (1)  ·  Lung Neoplasms (1)  ·  Melanoma (1)  ·  Nasopharyngeal Carcinoma (1)  ·  Neoplasms (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Prostatic Neoplasms (1)

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2)  ·  David Palma (2)  ·  Fudan University (2)  ·  Laboratorios Leti, S.L. (2)  ·  Aarhus University Hospital (1)  ·  Beijing Friendship Hospital (1)  ·  Binkui Li (1)  ·  Cell Genesys (1)  ·  Eye & ENT Hospital of Fudan University (1)  ·  Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1)  ·  Fujian Cancer Hospital (1)  ·  Institut Cancerologie de l'Ouest (1)  ·  Kong Fanming (1)  ·  Linnaeus Therapeutics, Inc. (1)  ·  Peking Union Medical College Hospital (1)

Countries

China (10)  ·  Canada (3)  ·  Australia (2)  ·  France (2)  ·  Netherlands (2)  ·  Spain (2)  ·  Sweden (2)  ·  Switzerland (2)  ·  United Kingdom (2)  ·  United States (2)  ·  Belgium (1)  ·  Denmark (1)  ·  Germany (1)  ·  India (1)  ·  Malaysia (1)

Top investigators

Binkui Li (1)  ·  David Palma, MD (1)  ·  Fuming Qiu, PhD (1)  ·  Hongmeng Yu (1)  ·  Johannes M Schmid, MD PhD (1)  ·  Juan Luis Anguita, MD (1)  ·  Pedro Guardia, MD (1)  ·  Ramakrishnan Madhusoodanan, PHD (1)  ·  Robert Olson, MD (1)  ·  Sanjun Cai, MD (1)  ·  Shankar Siva (1)  ·  Stephen Harrow, MB ChB (1)  ·  Suresh Senan, MRCP, FRCR (1)  ·  Xu Yujin, PhD (1)  ·  Zhen Zhang, MD (1)

Results publications

PMID 23740935, PMID 31426760, PMID 33608212, PMID 39244532, PMID 40367097, PMID 40953876